Company intelligence / Profile preview

QSAM Biosciences

Austin, Texas, United Statestelixpharma.com ↗

Ownership: Private
Employees: ~5
Development stage: Phase 1

Overview

CycloSam® (Samarium‑153 DOTMP) advanced through Phase I clinical trials targeting metastatic and primary bone cancers. The drug demonstrated potential for pain palliation and treatment of osteosarcoma, including pediatric patients. The company was acquired by Telix Pharmaceuticals in May 2024 to complement Telix’s oncology portfolio.

Therapeutic areas: Oncology
Modalities: Radiopharmaceutical
Industry: Biotech

Drug pipeline

1 asset

CycloSam

Phase 1

Indications: Bone metastases, Osteosarcoma, Ewing's sarcoma, Bone marrow ablation

Partnerships

RLS Inc. – Clinical and commercial supply agreement for radioisotope production and CDMO services [CycloSam® program support].

Beyond the preview

Go deeper on QSAM Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QSAM Biosciences.

Explore the full profile